New API cannabis products available for Australian compounding pharmacies

In addition to the cannabis product Bedrocan® (22% THC | < 1% CBD), Bedrocan has launched two new standardised cannabis products for compounding pharmacies in Australia: Bedropuur® and Bedrolina®. As of this year, these cannabis active pharmaceutical ingredient (API) products will be grown especially for the Australian market in Bedrocan’s brand new EU-GMP-certified production facility in Denmark. All these products will be available in flos and cut flos (granulate) forms in various packaging configurations.

Compounding pharmacies can use these API cannabis products to tailor cannabis medicines to patients’ individual needs. These products can be supplied in 400 or 3.000 grams packaging.

Cannabis for patients

Doctors can also prescribe these new medicinal cannabis products directly to patients. The Australian distributor Novachem delivers the products in 10-gram packages directly to pharmacies for patient use. These products can be administered by inhalation through a medical vaporizer offered by Storz & Bickel. The already available product Bedrocan® can also be administered using the metered-dose SyqeAir inhaler, a medical device developed by Syqe Medical, which contains Bedrocan® flos in its EU-GMP-certified cartridges.

*) Chemovar – a distinct species of Cannabis sativa L. defined by the chemical profile of its cannabinoids and terpenes.

Oral dosage form

Bedrocan is currently developing a new Bedrocan® oral dose form with different THC: CBD ratios. The plan is to launch these products later this year in different markets, including Australia. Additionally, the company is currently finalising the development of a new dose form for inhalaton, that will be initially available as a compounding product, and later potentially as a finished product. In 2026, other chemovars, such as Bedrobinol® and Bediol®, can also be supplied from Denmark to Australia, depending on the demand.